Citadel Advisors
SLDB icon

Citadel Advisors’s Solid Biosciences SLDB Stock Holding History

Citadel Advisors’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18.7M Sell
2,596,800
-67,063
-3% -$431K ﹤0.01% 2404
2025
Q4 		$15M Buy
2,663,863
+71,166
+3% +$386K ﹤0.01% 2703
2025
Q3 		$16M Buy
2,592,697
+69,404
+3% +$406K ﹤0.01% 2612
2025
Q2 		$12.3M Buy
2,523,293
+637,410
+34% +$2.25M ﹤0.01% 2747
2025
Q1 		$6.98M Buy
1,885,883
+937,465
+99% +$4.01M ﹤0.01% 3374
2024
Q4 		$3.79M Buy
948,418
+27,960
+3% +$154K ﹤0.01% 4426
2024
Q3 		$6.42M Buy
920,458
+808,044
+719% +$6.55M ﹤0.01% 3550
2024
Q2 		$637K Buy
112,414
+77,989
+227% +$698K ﹤0.01% 7544
2024
Q1 		$459K Buy
+34,425
New +$322K ﹤0.01% 8585
2023
Q2 		– Sell
-11,756
Closed -$55.7K – 15142
2023
Q1 		$55.7K Buy
+11,756
New +$70.6K ﹤0.01% 12019
2022
Q3 		– Sell
-4,683
Closed -$47.2K – 13524
2022
Q2 		$44K Buy
4,683
+3,992
+578% +$41.5K ﹤0.01% 12014
2022
Q1 		$12K Sell
691
-3,906
-85% -$68.9K ﹤0.01% 13362
2021
Q4 		$121K Buy
4,597
+3,239
+239% +$99K ﹤0.01% 12512
2021
Q3 		$49K Sell
1,358
-1,091
-45% -$46.3K ﹤0.01% 13384
2021
Q2 		$134K Sell
2,449
-164,468
-99% -$10.9M ﹤0.01% 12628
2021
Q1 		$13.8M Buy
166,917
+165,176
+9,487% +$18.3M ﹤0.01% 2496
2020
Q4 		$198K Buy
1,741
+578
+50% +$36.6K ﹤0.01% 9738
2020
Q3 		$35K Sell
1,163
-7,013
-86% -$269K ﹤0.01% 9721
2020
Q2 		$359K Buy
8,176
+2,825
+53% +$117K ﹤0.01% 7627
2020
Q1 		$192K Sell
5,351
-7,947
-60% -$393K ﹤0.01% 8048
2019
Q4 		$888K Sell
13,298
-11,044
-45% -$1.22M ﹤0.01% 5819
2019
Q3 		$3.78M Buy
24,342
+11,567
+91% +$1.31M ﹤0.01% 3510
2019
Q2 		$1.1M Sell
12,775
-21,917
-63% -$2.39M ﹤0.01% 5545
2019
Q1 		$4.79M Buy
+34,692
New +$8.69M ﹤0.01% 3061
2018
Q2 		– Sell
-2,098
Closed -$236K – 9252
2018
Q1 		$236K Buy
+2,098
New +$708K ﹤0.01% 7092

Other funds holding SLDB

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Citadel Advisors's SLDB Position: Q1 2026 in Review

Citadel Advisors reduced its Solid Biosciences (SLDB) stake by 2.5% in Q1 2026, selling an estimated $431K and leaving 2,596,800 shares worth $18.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2404.

Citadel Advisors first reported a position in SLDB in Q1 2018 and has held it in 25 quarters since. 150 funds tracked by Wall St. Rank hold SLDB as of Q1 2026.

  • Citadel Advisors held 2,596,800 shares of Solid Biosciences worth $18.7M as of Q1 2026.
  • Citadel Advisors sold 67,063 Solid Biosciences shares in Q1 2026, an estimated $431K.
  • Solid Biosciences made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #2404 holding.
  • Citadel Advisors first reported a position in Solid Biosciences in Q1 2018 and has held it in 25 quarters since.
  • 150 funds tracked by Wall St. Rank held Solid Biosciences as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.